$FLGT Under Securities Investigation After Missing Revenue Guidance

The molecular diagnostics sector faced fresh scrutiny this week as prominent securities litigation firm Lowey Dannenberg, P.C. announced an investigation into Fulgent Genetics Inc. ($FLGT) for potential violations of federal securities laws. The probe follows the company's February 27, 2026 earnings report, which revealed that full-year 2025 revenue fell short of updated guidance and marked a sequential decline in fourth-quarter performance—developments that have triggered investor concern and prompted the firm to encourage shareholders who experienced losses to come forward.

The Disappointing Earnings and Guidance Miss

Fulgent Genetics reported $322.7 million in full-year 2025 revenue, a result that fell short of the company's own updated guidance. More concerning for investors was the sequential decline in fourth-quarter revenue, a reversal that defied expectations in what is typically a stronger seasonal period for diagnostics companies. This performance gap between guidance and actual results is precisely the type of discrepancy that often triggers securities class action investigations, as it may suggest:

• Management overestimated demand visibility or pipeline strength
• Material business conditions deteriorated without proper disclosure
• Accounting practices may not have accurately reflected operational realities
• Investors relied on forward guidance that proved materially inaccurate

The investigation by Lowey Dannenberg specifically focuses on whether Fulgent Genetics and its officers violated Section 10(b) of the Securities Exchange Act and SEC Rule 10b-5, which prohibit fraudulent statements or omissions in connection with securities trading. The firm is actively soliciting investor participation, suggesting that damages may be substantial enough to warrant a coordinated legal response.

Market Context: Volatility in Molecular Diagnostics

The investigation arrives at a particularly sensitive time for the genetic testing and molecular diagnostics industry. This sector has experienced significant volatility in recent years as market dynamics shifted away from the pandemic-era boom that benefited companies like Fulgent Genetics. Several industry headwinds have converged:

Industry Challenges:

• Reimbursement pressures from insurers and government programs
• Increased competition in non-invasive prenatal testing (NIPT) and cancer genomics
• Normalization of testing volumes following post-COVID peaks
• Pricing pressures as competitors expand market share

Competitive Landscape: Fulgent Genetics operates in a crowded marketplace alongside established players and well-capitalized competitors. The company's exposure to clinical laboratory services and direct-to-consumer testing made it particularly vulnerable to the post-pandemic demand normalization that has plagued the sector. When guidance misses occur in this environment, they often signal deeper operational challenges rather than isolated quarterly fluctuations.

The February earnings report appears to have crystallized investor concerns about management's ability to accurately forecast business conditions—a critical credibility factor for high-growth diagnostics companies that command premium valuations based on expansion narratives.

Investor Implications: Legal Risk and Valuation Pressure

For shareholders of $FLGT, the Lowey Dannenberg investigation creates several immediate and longer-term concerns:

Near-Term Risks:

• Potential liability for the company if securities fraud is established
• Legal defense costs that will burden the balance sheet
• Management distraction and reputational damage
• Continued stock price pressure during litigation uncertainty
• Potential settlement costs that could materially impact cash reserves

Broader Market Implications: Securities investigations involving guidance misses are becoming increasingly common in the diagnostics sector, reflecting investor skepticism about forward-looking statements from management teams. This investigation may also prompt institutional investors to scrutinize other companies' guidance practices more carefully, particularly those with histories of volatile earnings or revenue misses.

For potential investors, the investigation adds another layer of due diligence required before establishing positions in $FLGT. The company's stock price likely faces pressure until clarity emerges regarding the investigation's scope and potential outcomes. Additionally, the miss raises fundamental questions about Fulgent Genetics' growth trajectory and management's execution capability—issues that extend well beyond the legal investigation itself.

Forward Outlook and Shareholder Considerations

As the investigation proceeds, Fulgent Genetics will face mounting pressure to provide transparency regarding the factors that led to the guidance miss and sequential revenue decline. Shareholders should monitor upcoming disclosures closely for:

• Management's explanation of business deterioration
• Changes in guidance methodology or disclosure practices
• Potential impacts on cash flow and capital allocation
• Any developments regarding settlement discussions or investigation conclusions

The investigation underscores a critical principle in equity markets: management credibility is difficult to restore once damaged. Guidance misses in the diagnostic testing sector often signal more systemic issues than isolated operational setbacks. Investors who purchased $FLGT shares based on management's forward outlook now face the prospect of extended litigation alongside fundamental business challenges.

For the broader investment community monitoring the molecular diagnostics space, the Lowey Dannenberg probe serves as a timely reminder that guidance discipline and transparent communication are essential—particularly when external conditions create genuine uncertainty. Fulgent Genetics now faces the dual challenge of rehabilitating its business performance while navigating potential securities litigation, a combination that will define shareholder value creation for years to come.